Compare BridgeBio Pharma Inc (BBIO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Southern Copper Corp — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Southern Copper Corp trades at $181.64 (market cap $152.16B). The key difference: Southern Copper Corp is far larger — about 9.2× BridgeBio Pharma Inc's market cap, and Southern Copper Corp pays a 2.17% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SCCO | |
|---|---|---|
Market Cap | $16.46B | $152.16B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $218.85 |
52-Week Low | $44.81 | $90.54 |
Enterprise Value | $18.02B | $154.22B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Southern Copper (SCCO) trades at $174.53, down 0.74% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 32.3% net income margin and consistent earnings beats, with Q1 2026 EPS of $1.90 exceeding the $1.82 estimate. Revenue grew to $13.42 billion in 2025, and cash flow from operations reached $4.75 billion. Recent corporate actions include a $1.00 dividend and a 1:1.01 stock split effective May 13, 2026.
The outlook for SCCO is supported by robust profitability and growth in the copper sector, driven by AI and infrastructure demand, but risks include high valuation multiples and bearish technical indicators. Analyst consensus is cautious with a $151.58 price target below the current price, indicating potential downside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
